CreativeOne Wealth LLC Buys 662 Shares of Stryker Co. (NYSE:SYK)

CreativeOne Wealth LLC increased its stake in shares of Stryker Co. (NYSE:SYK) by 46.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,078 shares of the medical technology company’s stock after buying an additional 662 shares during the quarter. CreativeOne Wealth LLC’s holdings in Stryker were worth $751,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the stock. Centennial Bank AR lifted its holdings in shares of Stryker by 106.7% during the second quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock valued at $32,000 after acquiring an additional 48 shares during the period. Darwin Wealth Management LLC acquired a new position in Stryker in the third quarter valued at about $36,000. HBW Advisory Services LLC bought a new stake in Stryker during the third quarter worth about $42,000. Hara Capital LLC acquired a new stake in shares of Stryker during the third quarter worth approximately $42,000. Finally, Grove Bank & Trust raised its stake in shares of Stryker by 84.8% in the third quarter. Grove Bank & Trust now owns 122 shares of the medical technology company’s stock valued at $44,000 after acquiring an additional 56 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. StockNews.com lowered Stryker from a “buy” rating to a “hold” rating in a research report on Friday, November 22nd. Evercore ISI raised their target price on Stryker from $380.00 to $384.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Royal Bank of Canada lifted their price target on Stryker from $386.00 to $400.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Citigroup increased their price objective on shares of Stryker from $406.00 to $411.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $420.00 target price (up from $380.00) on shares of Stryker in a research note on Wednesday, October 30th. Five investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $393.65.

Stryker Stock Performance

Shares of NYSE:SYK opened at $392.15 on Friday. The firm’s 50 day simple moving average is $368.51 and its 200 day simple moving average is $351.60. Stryker Co. has a fifty-two week low of $285.79 and a fifty-two week high of $398.20. The company has a market capitalization of $149.49 billion, a price-to-earnings ratio of 42.03, a P/E/G ratio of 2.93 and a beta of 0.91. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.10. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The company had revenue of $5.49 billion for the quarter, compared to analyst estimates of $5.37 billion. During the same period last year, the business posted $2.46 earnings per share. The business’s revenue for the quarter was up 11.9% compared to the same quarter last year. As a group, sell-side analysts forecast that Stryker Co. will post 12.06 earnings per share for the current year.

Insiders Place Their Bets

In other news, VP M Kathryn Fink sold 2,121 shares of Stryker stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $370.00, for a total transaction of $784,770.00. Following the transaction, the vice president now owns 10,042 shares in the company, valued at $3,715,540. The trade was a 17.44 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Kevin Lobo sold 57,313 shares of the business’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the transaction, the chief executive officer now owns 100,027 shares of the company’s stock, valued at $36,879,954.90. This represents a 36.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 66,781 shares of company stock worth $24,612,275. Corporate insiders own 5.90% of the company’s stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.